skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial

Abstract

Because curcumin's anti-inflammatory properties may protect the brain from neurodegeneration, we studied its effect on memory in non-demented adults and explored its impact on brain amyloid and tau accumulation using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile positron emission tomography (FDDNP-PET). Forty subjects (age 51–84 years) were randomized to a bioavailable form of curcumin (Theracurmin® containing 90 mg of curcumin twice daily [N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A) was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo) were determined in amygdala, hypothalamus, medial and lateral temporal, posterior cingulate, parietal, frontal, and motor (reference) regions. Mixed effects general linear models controlling for age and education, and effect sizes (ES; Cohen's d) were estimated. SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p <more » 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = -0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = -0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02). Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The FDDNP-PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.« less

Authors:
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1]
  1. Univ. of California, Los Angeles, CA (United States). Dept. of Psychiatry and Biobehavioral Sciences. Semel Inst. for Neuroscience and Human Behavior. UCLA Longevity Center. Dept. of Molecular and Medical Pharmacology. Center for Human Nutrition. David Geffen School of Medicine
Publication Date:
Research Org.:
Univ. of California, Los Angeles, CA (United States)
Sponsoring Org.:
USDOE; National Inst. of Health (NIH) (United States)
OSTI Identifier:
1437762
Alternate Identifier(s):
OSTI ID: 1505140
Grant/Contract Number:  
FC03-87ER60615; P01-AG025831; AG13308; P50 AG 16570; MH/AG58156; MH52453; AG10123; M01-RR00865
Resource Type:
Journal Article: Published Article
Journal Name:
The American Journal of Geriatric Psychiatry
Additional Journal Information:
Journal Volume: 26; Journal Issue: 3; Journal ID: ISSN 1064-7481
Publisher:
American Association for Geriatric Psychiatry - Elsevier
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; bioavailable curcumin; normal aging; memory; cognition; positron emission tomography

Citation Formats

Small, Gary W., Siddarth, Prabha, Li, Zhaoping, Miller, Karen J., Ercoli, Linda, Emerson, Natacha D., Martinez, Jacqueline, Wong, Koon-Pong, Liu, Jie, Merrill, David A., Chen, Stephen T., Henning, Susanne M., Satyamurthy, Nagichettiar, Huang, Sung-Cheng, Heber, David, and Barrio, Jorge R. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. United States: N. p., 2017. Web. doi:10.1016/j.jagp.2017.10.010.
Small, Gary W., Siddarth, Prabha, Li, Zhaoping, Miller, Karen J., Ercoli, Linda, Emerson, Natacha D., Martinez, Jacqueline, Wong, Koon-Pong, Liu, Jie, Merrill, David A., Chen, Stephen T., Henning, Susanne M., Satyamurthy, Nagichettiar, Huang, Sung-Cheng, Heber, David, & Barrio, Jorge R. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. United States. doi:10.1016/j.jagp.2017.10.010.
Small, Gary W., Siddarth, Prabha, Li, Zhaoping, Miller, Karen J., Ercoli, Linda, Emerson, Natacha D., Martinez, Jacqueline, Wong, Koon-Pong, Liu, Jie, Merrill, David A., Chen, Stephen T., Henning, Susanne M., Satyamurthy, Nagichettiar, Huang, Sung-Cheng, Heber, David, and Barrio, Jorge R. Fri . "Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial". United States. doi:10.1016/j.jagp.2017.10.010.
@article{osti_1437762,
title = {Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial},
author = {Small, Gary W. and Siddarth, Prabha and Li, Zhaoping and Miller, Karen J. and Ercoli, Linda and Emerson, Natacha D. and Martinez, Jacqueline and Wong, Koon-Pong and Liu, Jie and Merrill, David A. and Chen, Stephen T. and Henning, Susanne M. and Satyamurthy, Nagichettiar and Huang, Sung-Cheng and Heber, David and Barrio, Jorge R.},
abstractNote = {Because curcumin's anti-inflammatory properties may protect the brain from neurodegeneration, we studied its effect on memory in non-demented adults and explored its impact on brain amyloid and tau accumulation using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile positron emission tomography (FDDNP-PET). Forty subjects (age 51–84 years) were randomized to a bioavailable form of curcumin (Theracurmin® containing 90 mg of curcumin twice daily [N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A) was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo) were determined in amygdala, hypothalamus, medial and lateral temporal, posterior cingulate, parietal, frontal, and motor (reference) regions. Mixed effects general linear models controlling for age and education, and effect sizes (ES; Cohen's d) were estimated. SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = -0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = -0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02). Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The FDDNP-PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.},
doi = {10.1016/j.jagp.2017.10.010},
journal = {The American Journal of Geriatric Psychiatry},
issn = {1064-7481},
number = 3,
volume = 26,
place = {United States},
year = {2017},
month = {10}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1016/j.jagp.2017.10.010

Citation Metrics:
Cited by: 10 works
Citation information provided by
Web of Science

Save / Share: